http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite To Stand With Science
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite to Stand with Science
-
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference
-
Merck (MRK) Says New Scientific Data at the ESMO Virtual Congress 2020 Reflect its Commitment to Advancing Cancer Research and Care
-
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
-
Merck's (MRK) KEYTRUDA Receives Two New Approvals in Japan
-
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
-
Merck's (MRK) KEYTRUDA in Combination With Chemotherapy Significantly Improved OS and PFS Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer
-
Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line
-
Merck Animal Health Completes Acquisition of IdentiGEN
-
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
-
Merck (MRK) Animal Health Completes Acquisition of Worldwide Rights to VECOXAN Brand of Parasiticides for Ruminant Portfolio
-
Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio
-
Merck Announces Second-Quarter 2020 Financial Results
-
Merck (MRK) Announces Two US Regulatory Milestones for KEYTRUDA in Triple-Negative Breast Cancer
-
Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)
-
Merck (MRK) Announces FDA Grants Breakthrough Therapy Designation to Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With VHL- Associated RCC
-
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
-
Merck Announces Fourth-Quarter 2020 Dividend
-
Factbox: More companies join Facebook ad boycott bandwagon
-
Merck (MRK) Announces FDA Grants Priority Review to its NDA for Vericiguat
-
FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat
-
MilliporeSigma Opens its Largest M Lab™ Collaboration Center in Shanghai
-
Merck (MRK) Animal Health Receives U.S. FDA Approval of BRAVECTO Monthly Chews
-
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews
-
Merck (MRK) Announces FDA Grants Priority Review to its sBLA for KEYTRUDA for Second-Line Treatment of Patients With R/R Classical Hodgkin Lymphoma
-
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Ly
-
Merck Announces Appointment of Organon & Co. General Counsel
-
AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Approved in EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
-
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
-
Merck (MRK) and Eisai Receive CRL for KEYTRUDA plus LENVIMA Combination as First-Line Treatment for Unresectable HCC
-
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
-
Merck (MRK) Reports New Analyses Showing Additional Safety & Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
-
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
-
Virbac completes divestment of U.S. Rights to SENTINEL® brands to MSD Animal Health
-
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
-
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
-
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
-
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
-
Merck (MRK) Announces FDA Approves its KEYTRUDA for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
-
Merck (MRK) Announces FDA Approves KEYTRUDA for Treatment of Patients with Recurrent or Metastatic cSCC that is Not Curable by Surgery or Radiation
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
-
Merck (MRK) Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
-
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
-
Merck (MRK) Announces V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
-
Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
-
Merck (MRK) Announces KEYTRUDA Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
